Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of pomaglumetad methionil in schizophrenia
2011-004327-13Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of pomaglumetad methionil in schizophrenia (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Categorical changes in extrapyramidal symptom scales. Started Dec 2011; status: terminated.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2011-004327-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004327-13.